Denali Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $0.0 | $330.5 | $105.1 | $48.7 |
| Operating income | -$555.3 | -$487.3 | -$196.7 | -$340.7 | -$295.8 |
| Net income | -$512.5 | -$422.8 | -$145.2 | -$326.0 | -$290.6 |
| Cash Flow Statement | |||||
| Free cash flow | -$422.1 | -$363.6 | -$370.9 | -$262.5 | -$219.9 |
Shares outstanding 159.8M · Free float 89.5%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.